Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ellen K. Ritchie
How Do Preexisting Autoimmune Diseases Impact MPN Treatments?
Up Next Managing Stress and Fatigue Over the Holidays slide, 1 of 1 is in view. Share via facebook Share via twitter Share via mail Our Review Process In this clip from Answers Now: Preventing and Reducing Comorbidities in MPNs, Ellen Ritchie, MD, associate professor, Weill Cornell Medicine, explains how having a preexisting autoimmune disease can impact your treatment choice for myeloproliferative neoplasms (MPNs).
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
February 22, 2024 N Engl J Med 2024; 390:723-735 DOI: 10.1056/NEJMoa2308809 Abstract Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Despite advances in frontline treatment with recently approved therapies for acute myeloid leukemia (AML), most patients experience relapsed/refractory (R/R) disease.1,2 R/R AML has a median overall survival (OS) of 4-7 months with standard chemotherapy approaches,3-7 emphasizing the importance of newly approved targeted therapies and the need for additional treatment options.8-10 CONTEXT Key Objective The FLT3 inhibitor gilteritinib is highly active in advanced, FLT3-mutated (FLT3mut) acute...
Edinburgh Festivals Future Uncertain, Says Director
The Director of Festivals Edinburgh, the organisation that overseas Edinburgh’s 11 major cultural events, has said that extra funding is needed to tackle growing criticism about the impact of large-scale events in the city.
What Women with MPNs Need to Know
View All In Series Published on December 17, 2020 Doctor Shares Advice for Women with MPNs Does gender affect the way that MPNs present? In some ways yes — and in other ways, no! In this segment of Answers Now: Facing MPNs, an expert and MPN patient advocate will cover everything women with MPNs need to know and offer helpful advice.
New Treatments and Clinical Trials for Essential Thrombocythemia
View next Published on August 28, 2020 What's the Latest Treatment News and Available Clinical Trials for Essential Thrombocythemia? What clinical trials are available for MPN patients with essential thrombocythemia (ET)? Are there new treatments for ET in development? In this segment from a recent MPN Answers Now program, host Andrew Schorr gets answers to these questions plus more from Dr. Ellen Ritchie from Weill Cornell Medicine. This is Part 3 of a 4-part series.
Diet, Exercise and Supplements for Essential Thrombocythemia (MPN) patients
View next Published on August 27, 2020 Is There a Recommended Diet or Exercise for People with Essential Thrombocythemia (ET)? What is the best diet for essential thrombocythemia patients? How important is daily exercise if you have an MPN? Are there supplements patients should take? In this segment from a recent MPN Answers Now program, host Andrew Schorr talks to Dr. Ellen Ritchie from Weill Cornell Medicine about what essential thrombocythemia patients can do to stay healthy. Watch to learn more.
Essential Thrombocythemia (ET) Treatments Currently Available
Diagnosing Essential Thrombocythemia Andrew Schorr: So Dr. Ritchie, I've got a few questions for you as we start. I know that there are 70,000 to 80,000 people in the U.S. living with essential thrombocythemia, more often women than men, but often people take a while to be diagnosed. Why do some people get misdiagnosed? Why is it hard? Dr. Ritchie: For several reasons.
Essential Thrombocythemia (ET) and COVID-19 Complications
View next Published on August 19, 2020 Does Having ET Mean I'm at Risk For COVID-19 Complications? Are essential thrombocythemia patients at a higher risk of developing complications from COVID-19 because of the clotting nature of their myeloproliferative neoplasm?
Latest COVID-19 Information for MPN Patients
View next Published on June 4, 2020 Should I get tested for COVID-19? What precautions should I take as states open back up? Is it okay for family members to visit? What about talking to neighbors if I pass them in the street? In Part 2 of our recent Answers Now program, host and MPN patient Andrew Schorr got your questions answered by MPN experts Dr. Ellen Ritchie from Weill Cornell in NYC and Dr. Brady Stein from Lurie Cancer Center.
COVID-19 Testing for MPN Patients
View next Published on June 3, 2020 Have any MPN patients gotten COVID-19? Should you get tested? What precautions should you take? Watch as host and MPN patient Andrew Schorr talks to Ruth Fein, an MPN patient who experienced COVID-19 symptoms. He then gets the facts from Ruth’s doctor, Dr. Ellen Ritchie from Weill Cornell Medicine in NYC, along with Dr. Brady Stein from Robert H. Lurie Comprehensive Cancer Center.
“Like Riding a Roller Coaster”: An AML Patient’s View on the Emotional Impact of 27 Years With Cancer
Topics include: Treatment , Treatment Journey | Survivorship and Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Beth Probert: So, Jim. You are a long-time survivor. How has your cancer diagnosis impacted you emotionally?
When Should AML Patients Consider a Transplant?
Topics include: Treatment | General , Treatment and Understanding Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Andrew Schorr: So, first of all, I’m living with myelofibrosis and know that there’s a percentage of people who progress to secondary AML.
Clinical Trial Participation: Propelling Advances in AML Treatment
Can you help in the advancement in the treatment of acute myeloid leukemia (AML)? AML experts Dr. Ellen Ritchie from Weill Cornell Medicine and Dr. Tapan Kadia from MD Anderson Cancer Center speak on how important clinical trials are and how they can move forward the advancement of AML treatments for all patients. In the US, only 5 percent of patients participate in clinical trials and this could be hindering our chances for advancement in treatments.
ASH 2018 AML Treatment and Research Updates From an Expert Roundtable
As part of Patient Power’s on-site coverage of the 2018 American Society of Hematology (ASH) annual meeting in San Diego, CA, founders Andrew and Esther Schorr hosted an expert roundtable to review acute myeloid leukemia (AML) news announced at the conference. AML experts, Dr. Sangmin Lee and Dr. Ellen K. Ritchie, both from Weill Cornell Medicine, and Dr. Tapan M.
Acute Myeloid Leukemia (AML)
Become a member to access our latest content and be the first to know about new programs and information.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ellen K.
Contact Ellen K., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack